LPLukas Pin

Lukas Pin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lukas Pin has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adaptive versus fixed designs in confirmatory clinical trials: centering the choice on ethics

    by Stef Baas, Lukas Pin, David S. Robertson, Frank Bretz, Hearn Jay Cho, Laura Flight, Rieke van der Graaf, Mackenzie Graham, Peter Jacko, Thomas Jaki, et al.

    Background: Because confirmatory clinical trials are costly, large-scale endeavors, the choice of their design carries significant weight. While the current methodological landscape offers tools to address residual pre-trial uncertainty through prespecified adaptations to design elements, design choices remain frequently constrained by prevailing orthodoxies. Methods: We examine how unacknowledged design uncertainties (e.g., sample size calculations based on incorrect effect size or variance estimates) impact the statistical, ethical, and resource-stewardship goals of confirmatory trials. We contrast how fixed and adaptive design strategies handle these uncertainties, detailing the operational safeguards, firewalls, and trade-offs (e.g., complexity, operational bias) required to preserve trial integrity. Results: Strict adherence to default templates prevents stakeholders from matching the design strategy to the specific complexities of the research question. We observe that the gold standard status of fixed designs often obscures their limitations in handling design uncertainties. A rigid adherence to these conventions can ethically hinder a trial’s ability to deliver conclusive results. Conversely, while adaptive designs can offer tools to efficiently reduce uncertainty, we acknowledge that adaptive elements are not without cost; their implementation requires rigorous safeguards to manage specific risks to trial integrity and potential operational biases. Conclusion: To better align clinical research with its ethical and scientific mandates, we issue two calls to action. First, trial designers, including statisticians, must clearly articulate how target and design uncertainties impact ethical obligations, promoting an open-minded evaluation of both fixed and adaptive methods. Second, stakeholders must foreground ethical considerations during design selection, requiring explicit justification for the use—or non-use—of adaptive elements. The ethical path forward is not to default to the old or blindly adopt the new, but to explicitly justify the chosen design based on its responsiveness to the specific uncertainties of the trial. We posit that trial design must transition from a habit-based process to one where pre-trial uncertainties are openly discussed and addressed.

  • Open Access

    Rejoinder: “Adaptive versus fixed designs in confirmatory clinical trials: Centering the choice on ethics”

    by Stef Baas, Lukas Pin, David S. Robertson, Alex John London, Mark Sheehan, Sofía S. Villar


  • Open Access

    Safety‐Driven Response Adaptive Randomization: An Application in Noninferiority Oncology Trials

    by Maria Vittoria Chiaruttini, Lukas Pin, Sofía S. Villar

    The majority of response‐adaptive randomization (RAR) designs in the literature rely on efficacy data to guide dynamic patient allocation. However, their applicability becomes limited in settings where efficacy outcomes, such as survival, are observed with a random delay. To address this limitation, we introduce SAFER, a novel RAR design that leverages early‐emerging safety data to inform treatment allocation decisions, particularly in oncology trials. The design is broadly applicable to contexts where prioritizing the arm with superior safety is desirable. This is especially relevant in noninferiority trials, to demonstrate that an experimental treatment is not inferior to the standard of care, while potentially offering improved tolerability. In such trials, an unavoidable trade‐off arises: maintaining statistical efficiency for the efficacy hypothesis while integrating safety‐driven adaptations through RAR. The SAFER design addresses this trade‐off by dynamically adjusting the allocation proportion based on the observed association between safety and efficacy endpoints. We illustrate the performance of SAFER through a simulation study inspired by the CAPP‐IT Phase III oncology trial. Results show that SAFER preserves statistical power, reduces the adverse event rate, and offers flexible adaptation speed depending on the temporal alignment of the endpoints.

  • Open Access

    A burn-in(g) question: How long should an initial equal randomization stage be before Bayesian response-adaptive randomization?

    by Edwin Yn Tang, Stef Baas, Daniel Kaddaj, Lukas Pin, David S Robertson, Sofía S Villar

    Response-adaptive randomization (RAR) can increase participant benefit in clinical trials, but also complicates statistical analysis. The burn-in period—a non-adaptive initial stage—is commonly used to mitigate this disadvantage, yet guidance on its optimal duration is scarce. To address this critical gap, this paper introduces an exact evaluation approach to investigate how the burn-in length impacts statistical operating characteristics of two-arm binary Bayesian RAR (BRAR) designs. We show that (1) commonly used calibration and asymptotic tests show substantial type I error rate inflation for BRAR designs without a burn-in period, and increasing the total burn-in length to more than half the trial size reduces but does not fully mitigate type I error rate inflation, necessitating exact tests; (2) exact tests conditioning on total successes show the highest average and minimum power up to large burn-in lengths; (3) the burn-in length substantially influences power and participant benefit, which are often not maximized at the maximum or minimum possible burn-in length; (4) the test statistic influences the type I error rate and power; (5) estimation bias decreases quicker in the burn-in length for larger treatment effects and increases for larger trial sizes under the same burn-in length. Our approach is illustrated by re-designing the ARREST trial.


  • Open Access

    Informed Burn-In Decisions in RAR: Harmonizing Adaptivity and Inferential Precision Based on Study Setting

    by Lukas Pin, Stef Baas, Gianmarco Caruso, David S. Robertson, Sofía S. Villar

    Response-Adaptive Randomization (RAR) is recognized for its potential to deliver improvements in patient benefit. However, the utility of RAR is contingent on regularization methods to mitigate early instability and preserve statistical integrity. A standard regularization approach is the ''burn-in'' period, an initial phase of equal randomization before treatment allocation adapts based on accrued data. The length of this burn-in is a critical design parameter, yet its selection remains unsystematic and improvised, as no established guideline exists. A poorly chosen length poses significant risks: one that is too short leads to high estimation bias and type-I error rate inflation, while one that is too long impedes the intended patient and power benefits of using adaptation. The challenge of selecting the burn-in generalizes to a fundamental question: what is the statistically appropriate timing for the first adaptation? We introduce the first systematic framework for determining burn-in length. This framework synthesizes core factors - total sample size, problem difficulty, and two novel metrics (reactivity and expected final allocation error) - into a single, principled formula. Simulation studies, grounded in real-world designs, demonstrate that lengths derived from our formula successfully stabilize the trial. The formula identifies a ''sweet spot'' that mitigates type-I error rate inflation and mean-squared error, preserving the advantages of higher power and patient benefit. This framework moves researchers from conjecture toward a systematic, reliable approach.

  • Open Access

    Revisiting optimal allocations for binary responses: insights from considering type-I error rate control

    by Lukas Pin, Sofía S Villar, William F Rosenberger

    This work revisits optimal response-adaptive designs from a type-I error rate perspective, highlighting when and how much these allocations exacerbate type-I error rate inflation—an issue previously undocumented. We explore a range of approaches from the literature that can be applied to reduce type-I error rate inflation. However, we found that all of these approaches fail to give a robust solution to the problem. To address this, we derive 2 optimal allocation proportions, incorporating the more robust score test (instead of the Wald test) with finite sample estimators (instead of the unknown true values) in the formulation of the optimization problem. One proportion optimizes statistical power, and the other minimizes the total number of failures in a trial while maintaining a fixed variance level. Through simulations based on an early phase and a confirmatory trial, we provide crucial practical insight into how these new optimal proportion designs can offer substantial patient outcomes advantages while controlling type-I error rate. While we focused on binary outcomes, the framework offers valuable insights that naturally extend to other outcome types, multi-armed trials, and alternative measures of interest.


  • Open Access

    Randomization‐Based Inference for MCP‐Mod

    by Lukas Pin, Oleksandr Sverdlov, Frank Bretz, Björn Bornkamp

    Dose selection is critical in pharmaceutical drug development, as it directly impacts therapeutic efficacy and patient's safety of a drug. The Generalized Multiple Comparison Procedures and Modeling approach is commonly used in Phase II trials for testing and estimation of dose‐response relationships. However, its effectiveness in small sample sizes, particularly with binary endpoints, is hindered by issues like complete separation in logistic regression, leading to non existence of estimates. Motivated by an actual clinical trial using the MCP‐Mod approach, this paper introduces penalized maximum likelihood estimation (MLE) and randomization‐based inference techniques to address these challenges. Randomization‐based inference allows for exact finite sample inference, while population‐based inference for MCP‐Mod typically relies on asymptotic approximations. Simulation studies demonstrate that randomization‐based tests can enhance statistical power in small to medium‐sized samples while maintaining control over type‐I error rates, even in the presence of time trends. Our results show that residual‐based randomization tests using penalized MLEs not only improve computational efficiency but also outperform standard randomization‐based methods, making them an adequate choice for dose‐finding analyses within the MCP‐Mod framework. Additionally, we apply these methods to pharmacometric settings, demonstrating their effectiveness in such scenarios. The results in this paper underscore the potential of randomization‐based inference for the analysis of dose‐finding trials, particularly in small sample contexts.


  • Open Access

    Response-Adaptive Randomization Designs Based on Optimal Allocation Proportions

    by Lukas Pin, Sofia S. Villar, William F. Rosenberger

    This book chapter discusses response-adaptive randomization procedures which are based on optimal allocation proportions, e.g. derived from theoretical optimization problems. We elucidate the objectives of these proportions, emphasizing their role in maximizing statistical power and/or enhancing patient benefit. Moreover, practical insights on estimation and targeting of these allocation proportions are provided. A clinical trial example, the CALISTO trial, illustrates the application of these procedures. We aim to provide an overview that serves as a basis for discussions about optimal allocation proportions, assists in their implementation in practice and highlights future research areas.